Preoperative stereotactic radiosurgery as neoadjuvant therapy for resectable brain tumors
ConclusionEarly clinical data is very promising for neoadjuvant SRS in the setting of brain metastases. There are three ongoing phase III trials that will be more definitive in evaluating the potential benefits. While there is less data available for neoadjuvant SRS for gliomas, there remains a potential role, particularly to enable dose escalation and increase immunogenic effects.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Glioma | Men | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Neurology | Radiation Therapy